Transaction|February 18, 2015
Transition Therapeutics completes US$23 million public offering of common shares
Torys acted as Canadian counsel to the syndicate of underwriters led by Cowen and Company with a team that included Cheryl Reicin, Eric Foster and Marissa Daniels.
On February 18, 2015, Transition Therapeutics Inc. (Transition) successfully completed its issuance of 3,538,461 common shares at a price of US$6.50 per common share for gross proceeds of approximately US$23 million. The underwriting syndicate for the offering was led by Cowen and Company, LLC.
Transition is a biopharmaceutical development company, advancing novel therapeutics for CNS and metabolic disease indications.
Further information can be found on Transition's website.